# NCT03539536 (NCT03539536)

> Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03539536
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Non-small Cell Lung Cancer
- Interventions: Telisotuzumab vedotin
- Enrollment: 270
- Primary outcome: Overall Response Rate (ORR) (Stage 1 and Stage 2)
- Primary outcome: Number of Participants with Adverse Events (Alternate dose cohort)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03539536